EUVIMEDEUVIMED entdecken
Crossref

Discovery of Highly Selective and Potent Macrocyclic JAK2 Inhibitors for the Treatment of MPNs

Songhui Qin, Rui Wu, Yang Tian, Minghai Tang, Wei Yan, Xiaobo Cen iD, Lijuan Chen iD, Tao Yang iD

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c01686 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Songhui Qin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Natural and Targeted Small Molecule Drugs, State Key Laboratory of Biotherapy and Cancer Center; West China Hospital; Sichuan Universit…. Hauptthemen laut MEDLINE: Janus Kinase 2, Protein Kinase Inhibitors, Drug Discovery, Macrocyclic Compounds. Die Arbeit nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China, 1?3?5 Project for Disciplines of Excellence, West China Hospital, Sichuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of selective JAK2 inhibitors represents a promising therapeutic strategy for MPNs. Building upon the foundation of our first-generation JAK2 inhibitor, we employed macrocyclization-driven structural optimization to address its off-target limitations. This strategy yielded a novel class of macrocyclic JAK2 inhibitors, with compound 15au emerging as a standout candidate through systematic SAR studies. Compound 15au exhibits potent JAK2 inhibition (IC50 = 2 nM), coupled with enhanced kinase selectivity, demonstrating 89.5-, 80.5-, and 51-fold selectivity over JAK1, JAK3, and TYK2, respectively. Mechanistic studies confirm its ability to suppress the JAK2/STAT5 signaling pathway. 15au demonstrates good pharmacokinetic properties, achieving high Cmax and AUC0-t. These properties enable remarkable in vivo efficacy, where 15au outperforms both pacritinib and fedratinib in MPN models at lower doses. This work validates macrocyclization as an effective strategy for refining JAK2 inhibitors, simultaneously enhancing kinase selectivity, metabolic stability, and efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase 2Protein Kinase InhibitorsDrug DiscoveryMacrocyclic CompoundsHumansAnimalsStructure-Activity RelationshipMiceSignal Transduction

Substanzen

Janus Kinase 2Protein Kinase InhibitorsJAK2 protein, humanMacrocyclic Compounds

Autor:innen und Institutionen

  • Laboratory of Natural and Targeted Small Molecule Drugs, State Key Laboratory of Biotherapy and Cancer Center; West China Hospital; Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu 610041, C…
  • Department of Otolaryngology Head and Neck Surgery, Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, Sichuan 610014, China.
  • Medical Research Center, Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, Sichuan 610031, China.
  • National Chengdu Center for Safety Evaluation of Drugs, West China Hospital of Sichuan University, Chengdu 610041, China.

ORCID-Profile: Xiaobo Cen, Lijuan Chen, Tao Yang

Förderung

  • National Natural Science Foundation of China
  • 1?3?5 Project for Disciplines of Excellence, West China Hospital, Sichuan University

Zitieren

APA

Qin, S., Wu, R., Tian, Y., Tang, M., Yan, W., Cen, X., Chen, L., & Yang, T. (2025). Discovery of Highly Selective and Potent Macrocyclic JAK2 Inhibitors for the Treatment of MPNs. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01686

Vancouver

Qin S, Wu R, Tian Y, Tang M, Yan W, Cen X, et al. Discovery of Highly Selective and Potent Macrocyclic JAK2 Inhibitors for the Treatment of MPNs. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c01686

BibTeX
@article{Qin2025,
  author = {Qin, Songhui and Wu, Rui and Tian, Yang and Tang, Minghai and Yan, Wei and Cen, Xiaobo and Chen, Lijuan and Yang, Tao},
  title = {Discovery of Highly Selective and Potent Macrocyclic JAK2 Inhibitors for the Treatment of MPNs},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c01686}
}
Kostenlos starten →